Yardley, D A
Tripathy, D
Brufsky, A M
Rugo, H S
Kaufman, P A
Mayer, M
Magidson, J
Yoo, B
Quah, C
Ulcickas Yood, M
Article History
Received: 9 December 2013
Revised: 6 March 2014
Accepted: 8 March 2014
First Online: 17 April 2014
Competing interests
: AMB and PAK have received consulting fees from Genentech Inc./F. Hoffmann La-Roche, Ltd. DT has served in an uncompensated capacity on a steering committee and receives research funding (paid to his institution) for a registry study funded by Genentech, Inc./F. Hoffmann La-Roche, Ltd. MUY has served on an advisory board for Genentech, Inc. HSR has received research funding for her institution from Genentech, Inc. and GlaxoSmithKline; PAK has received research funding for his institution from Genentech, Inc. JM has received consulting fees from Genentech Inc. and has a financial interest in the Latent GOLD software package. BY and CQ are full-time employees of Genentech, Inc. and own stock in F. Hoffmann La-Roche Ltd. The other authors declare no conflict of interest.